Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) pathways are crucial in immune regulation.
• These pathways are known predictors of response to targeted therapies.
• Primary central nervous system lymphomas (PCNSLs) are a distinct group of non-Hodgkin lymphomas.

Purpose of the Study:

• To investigate the expression patterns of PD-L1 in PCNSL tissues.
• To explore the correlation between PD-L1 expression and other immune markers.
• To assess the prognostic significance of PD-L1 expression in PCNSL patients.

Main Methods:

• PD-L1 protein and mRNA expression were quantified in 64 PCNSL tissue samples.
• mRNA expression of IFN-γ, IL-10, CD4, and CD8 was also evaluated.
• Statistical analyses were performed to determine correlations and survival impacts.

Main Results:

• PD-L1 protein was detected in tumor microenvironments (52%) and tumor cells (4.1%).
• PD-L1 mRNA positively correlated with IFN-γ and CD4 mRNA expression.
• Tumor cell PD-L1 expression showed a positive correlation with overall survival, while microenvironmental PD-L1 had an insignificant negative trend.

Conclusions:

• PD-L1 is expressed in both tumor cells and the tumor microenvironment in PCNSL.
• PD-L1 expression, particularly on tumor cells, may have prognostic implications for overall survival in PCNSL.
• Further research is warranted to elucidate the biological roles of PD-L1 in PCNSL.